The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Ventyx Biosciences Inc (NASDAQ: VTYX) closed at $2.39 down -2.85% from its previous closing price of $2.46. In other words, the price has decreased by -$2.85 from its previous closing price. On the day, 1.41 million shares were traded. VTYX stock price reached its highest trading level at $2.49 during the session, while it also had its lowest trading level at $2.35.
Ratios:
For a deeper understanding of Ventyx Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.19 and its Current Ratio is at 14.19. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on March 12, 2024, Upgraded its rating to Overweight and sets its target price to $16 from $7 previously.
On March 12, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $12.
Wells Fargo Downgraded its Overweight to Equal Weight on November 07, 2023, whereas the target price for the stock was revised from $77 to $8.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 02 ’24 when Krueger Christopher W sold 1,651 shares for $5.40 per share. The transaction valued at 8,921 led to the insider holds 284,999 shares of the business.
Nuss John sold 1,651 shares of VTYX for $8,921 on Apr 02 ’24. The CHIEF SCIENTIFIC OFFICER now owns 264,998 shares after completing the transaction at $5.40 per share. On Apr 02 ’24, another insider, Mohan Raju, who serves as the CEO AND PRESIDENT of the company, sold 4,312 shares for $5.40 each. As a result, the insider received 23,299 and left with 1,578,250 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VTYX now has a Market Capitalization of 168899168 and an Enterprise Value of -59273776.
Stock Price History:
Over the past 52 weeks, VTYX has reached a high of $36.19, while it has fallen to a 52-week low of $1.79. The 50-Day Moving Average of the stock is 4.66%, while the 200-Day Moving Average is calculated to be -33.15%.
Shares Statistics:
For the past three months, VTYX has traded an average of 1.28M shares per day and 2311250 over the past ten days. A total of 59.24M shares are outstanding, with a floating share count of 54.69M. Insiders hold about 22.62% of the company’s shares, while institutions hold 71.58% stake in the company. Shares short for VTYX as of 1724976000 were 8559631 with a Short Ratio of 6.74, compared to 1722384000 on 9006148. Therefore, it implies a Short% of Shares Outstanding of 8559631 and a Short% of Float of 14.180000000000001.
Earnings Estimates
The market rating of Ventyx Biosciences Inc (VTYX) is currently shaped by the ongoing analysis conducted by 8.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.58, with high estimates of -$0.44 and low estimates of -$0.81.
Analysts are recommending an EPS of between -$1.94 and -$2.5 for the fiscal current year, implying an average EPS of -$2.16. EPS for the following year is -$2.22, with 8.0 analysts recommending between -$1.71 and -$3.14.
